Based on our findings, we asked whether the FLT3 inhibitors, which are developed for AML patients, could be repurposed for FLT3+ BP-CML patients to restore BCR::ABL1 TKI sensitivity and prevent BP progression. Here, FLT3 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.